Catalyst
Slingshot members are tracking this event:
FDA Approves Merck’s KEYTRUDA (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| MRK |
|
|
||||
Additional Information
The approval is based on data from the KEYNOTE-012 study, which included patients with recurrent or metastatic HNSCC who had disease progression on or after platinum-containing chemotherapy or following platinum-containing chemotherapy administered as part of induction, concurrent, or adjuvant therapy and ECOG performance status (PS) of zero or one. The data showed an objective response rate (ORR) of 16 percent (95% CI: 11, 22), complete response rate of five percent, with responses of six months or longer observed in 82 percent (n=23/28) of the responding patients. ORR and duration of response were similar regardless of human papilloma virus (HPV) status.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 09, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Keytruda, Head And Neck Squamous Cell Carcinoma, Platinum-containing Chemotherapy, Keynote-012, Human Papilloma Virus, Hpv, Metastatic Hnscc, Recurrent Hnscc, Pd-l1
